Acorda Therapeutics is a publicly traded (NASDAQ: ACOR) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders.
We started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders.
We have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. We achieve our goals by:
• investing in research and development
• collaborating closely with the patient, medical and scientific communities
• retaining employees with compassion and commitment
Acorda has been voted one of the best companies to work for in New York for the past five years in a row, as a result of our dynamic environment, strong corporate culture, significant emphasis on research and development, and a robust product pipeline. We are positioned to be an industry leader, poised for exceptional growth.
Closing share price
|FY, 2015||FY, 2014||FY, 2013|
|$493 M||$401 M||$336 M|
Revenue growth, %
|$400 M||$321 M||$270 M|
|$34 M||$36.4 M||$30.4 M|
Operating expense total
|$459 M||$365 M||$306 M|
|$11.1 M||$17.7 M||$16.4 M|
Operating cash flow
|$-29 M||$134 M||$6.16 M|